

## PD-L1 Protein, Human, Recombinant (His), PE-Labeled

### General Information

Synonyms:	B7H1;PDCD1L1;B7-H1;PD-L1;PDCD1LG1;hPD-L1;PDL1;B7-H
Protein Construction:	A DNA sequence encoding the Human CD274 (NP_054862.1) (Met1-Thr239) was expressed with a polyhistidine tag at the C-terminus. The protein is site-specifically labeled with PE (Excitation = 495-566 nm, Emission Max. = 575 nm).
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q9NZQ7-1
Molecular Weight:	28.8 kDa (predicted)

### QC Testing

Biological Activity:	Flow cytometric analysis of anti-PD-L1 CAR expression. 293 cells were lentivirally transduced with anti-PD-L1 CAR. Flow cytometric analysis was performed with a negative control protein and PD-L1 Protein, Human, Recombinant (His), PE-Labeled (Cat#TMPY-07001), respectively. Non-transduced 293 cells were used as a control (left).
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	This product is Lyophilized from sterile PBS, pH 7.4, with 5 %-8 % trehalose and 0.2% BSA. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

### Preparation and Storage

Reconstitution:	Please refer to the lot-specific COA.
Stability & Storage:	Twelve months from date of receipt at -20°C to -70°C in lyophilized form and 3 months at -70°C under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles. <small>Actual storage temperature shall be subject to the COA.</small>
Shipping:	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1 (PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by

inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. Cancer Immunotherapy Co-inhibitory Immune Checkpoint Targets Immune Checkpoint Immune Checkpoint Blockade: Blocking Antibody Immune Checkpoint Blockade: PD-L1 / B7-H1 / CTLA-4 Immune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: FCM Antibodies Immune Checkpoint Detection: ICC Antibodies Immune Checkpoint Detection: IHC Antibodies Immune Checkpoint Detection: WB Antibodies Immune Checkpoint Proteins Immune Checkpoint Targets Immunotherapy PD-L1 / B7-H1 / CD274 Immune Checkpoint Proteins Targeted Therapy

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481